Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study

Neurology

Volumn 63, Issue 7, 2004, Pages 1245-1250

  Carroll, C B ^a,e   Bain, P O ^c   Teare, L ^b   Liu, X ^c   Joint, C ^d   Wroath, C ^a   Parkin, S G ^a   Fox, P ^b   Wright, D ^b   Hobart, J ^a   Zajicek, J P ^b  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d RADCLIFFE INFIRMARY   (United Kingdom)

^e ITTC Building ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; LEVODOPA; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRAWING; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 20844441058     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000140288.48796.8E     Document Type: Article

References (30)

1. Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996;22:382-385.
2. Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996;308:161-164.
3. Sieradzan KA, Fox SH, Hill M, Dick JPR, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
4. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002;17:1180-1187.
5. Venderova K, Ruzicka E, Visnovsky P. Cannabis and Parkinson's disease: subjective improvement of symptoms and drug-induced dyskinesias. Mov Disord 2002;17(suppl 5):S77. Abstract.
6. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000;14:1432-1438.
7. Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane WA, Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 1993;46:967-972.
8. Meschler JP, Hewlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology 2001;156:79-85.
9. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30:277-282.
10. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-1526.
11. Movement Disorder Society. Appendix: available dyskinesias clinical rating scales. Mov Disord 1999;14(suppl 1):75-80.
12. Katzenschlager R, Schrag A, Hobart J, Manson A, Evans A, Lees AJ. The impact of dyskinesias in Parkinson's disease: development of a patient-based outcome measure. J Neurol 2003;250(suppl 2):32.
13. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
14. Melamed E, Olanow CW, Nutt JG, Lang AE. Dyskinesias assessment workshop: reports from the working groups. Mov Disord 1999;14(suppl 1):69-73.
15. Jenkinson C, Fitzpatrick R, Peto V. The Parkinson's Disease Questionnaire. Health Services Research Unit. Oxford: Joshua Horgan Print Partnership, 1998.
16. McDowell I, Newell C. The McGill pain questionnaire. In: Measuring health: a guide to rating scales and questionnaires. Oxford: Oxford University Press, 1987.
17. Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 2001;22:75-76.
18. Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V, Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001;56:548-551.
19. Grundy RI, Rabuffetti M, Beltramo M. Cannabinoids and neuroprotection. Molec Neurobiol 2001;24:29-51.
20. Guzman M, Sanchez C, Galve-Roperh. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001;78:613-625.
21. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias. Arch Neurol 1999;56:1383-1386.
22. Carroll CB, Bain PG. Do on-off variations cause discrepancies in the historical items of the UPDRS? Mov Disord 2004;19:605.
23. Vitale C, Pellecchia MT, Grossi D, et al. Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci 2001;22:105-106.
24. Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord 1999;14:48-53.
25. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002;17:145-149.
26. Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 1999;14(suppl 1):13-18.
27. 2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res 1995;691:106-114.
28. 1 receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 1997;148:265-270.
29. Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord 2003;18:138-149.
30. Sanudo-Pena MC, Tsou K, Walker M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999;65:703-713.